FDA approves talazoparib plus enzalutamide for HRR gene-altered metastatic prostate cancer

FDA approval · CancerNetwork · 2026-10-26. Number 2 in the UrologyWatch Top 5 for October 27, 2026.

The FDA approved the combination of talazoparib and enzalutamide for patients with HRR gene-altered metastatic prostate cancer, expanding use of the PARP inhibitor-antiandrogen combination to an earlier treatment setting.

Why it matters: Provides an additional approved option for HRR-mutated metastatic prostate cancer patients, relevant to treatment sequencing decisions.

Source: CancerNetwork

The full October 27, 2026 edition · Today's urology news